Daewoong Lee, MD
Interventional Pain Medicine · Bloomington, INNPI 1477909703
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Relievant Medsystems, Inc. at 24.0% of the total. Reporting peaked in 2021 at $1,795 and has fallen 67.8% since, to $578 in 2025.
Across 77 payments — averaging $88.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Relievant Medsystems, Inc.$2K
- Medtronic$1K
- Boston Scientific$1K
- Nevro Corp.$603
- BD$550
- Globus Medical$507
- plus $879 from 7 others
What the payments were for
- Speaking & faculty fees$5508%
- Travel & lodging$3,19647%
- Food & beverage$2,50537%
- Education$5999%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Relievant Medsystems, Inc. | 9 | $1,645 |
| Medtronic(2 entities) | 12 | $1,487 |
| Boston Scientific | 16 | $1,180 |
| Nevro Corp. | 8 | $603 |
| BD | 1 | $550 |
| Globus Medical | 9 | $507 |
| Painteq LLC | 9 | $486 |
| Abbott | 7 | $146 |
| Si-bone, Inc. | 2 | $83 |
| Stryker | 1 | $57 |
| Nalu Medical, Inc. | 1 | $48 |
| SPR Therapeutics, Inc | 1 | $39 |
| Crossroads Orthopedics, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$2,833
- SUPERION$885
- INTELLIS$677
- KYPHON EXPRESS II KYPHOPAK TRAY$503
- PAINTEQ$366
- Omnia$347
- Vyrsa V1$258
- Senza Spinal Cord Stimulation System$117
How this compares
$6,850 in reported general payments places this provider in the 70th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 13 | $5,769 |
| Lidocaine | 34 | $2,833 |
| Tizanidine Hcl | 84 | $1,388 |
| Diclofenac Sodium | 32 | $811 |
| Gabapentin | 30 | $629 |
| Cefadroxil | 13 | $81 |
| Oxycodone Hcl | 13 | $29 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Bloomington
- Kamal TiwariBloomington$3K
- Joshua WellingtonCarmel$315K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Scott KimGreenwood$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.